Marianna Frascarelli, Tommaso Accinni, Antonino Buzzanca, Carlo Di Bonaventura, Martina Fanella, Carolina Putotto, Bruno Marino, Massimo Pasquini, Massimo Biondi, Claudio Colonnese, Fabio Di Fabio
{"title":"Similar grey matter abnormalities in 22q11.2DS and chronic schizophrenia: a voxel-based morphometry study.","authors":"Marianna Frascarelli, Tommaso Accinni, Antonino Buzzanca, Carlo Di Bonaventura, Martina Fanella, Carolina Putotto, Bruno Marino, Massimo Pasquini, Massimo Biondi, Claudio Colonnese, Fabio Di Fabio","doi":"10.1708/3964.39426","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The 22q11.2 Deletion Syndrome (22q11.2DS) is considered the most reliable biological model to study genetic vulnerability to schizophrenia. It appears useful to investigate neuroanatomical characteristics of people with 22q11.2DS compared to chronic schizophrenia and healthy controls.</p><p><strong>Methods: </strong>The sample consisted of 16 individuals with a diagnosis of schizophrenia for over 10 years (SCZ>10), 14 with a diagnosis for less than 10 years (SCZ≤10), 11 patients with 22q11.2DS with no diagnosis of psychotic disorder (DEL, n=11) and 19 healthy controls (HCs, n=19). Global intelligence (IQ) was evaluated for all subjects. Voxel-Based Morphometry (VBM) was employed to investigate potential differences between groups in grey matter volumes.</p><p><strong>Results: </strong>VBM located the most significant difference between SCZ and HCs in the left medial frontal gyrus, where SCZ>10 group showed a significant reduction of grey matter volume; the same cluster resulted significantly decreased in DEL group compared to HCs as well. Despite the extensive grey matter abnormalities observed in 22q11.2DS, the DEL group showed the only significant differences compared to the SCZ>10 group in the right lingual gyrus volumes.</p><p><strong>Conclusions: </strong>Despite the small sample, our study identified a common area of grey matter loss both in idiopathic schizophrenia and 22q11.2DS.</p>","PeriodicalId":21506,"journal":{"name":"Rivista di psichiatria","volume":"58 1","pages":"10-20"},"PeriodicalIF":1.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rivista di psichiatria","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1708/3964.39426","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The 22q11.2 Deletion Syndrome (22q11.2DS) is considered the most reliable biological model to study genetic vulnerability to schizophrenia. It appears useful to investigate neuroanatomical characteristics of people with 22q11.2DS compared to chronic schizophrenia and healthy controls.
Methods: The sample consisted of 16 individuals with a diagnosis of schizophrenia for over 10 years (SCZ>10), 14 with a diagnosis for less than 10 years (SCZ≤10), 11 patients with 22q11.2DS with no diagnosis of psychotic disorder (DEL, n=11) and 19 healthy controls (HCs, n=19). Global intelligence (IQ) was evaluated for all subjects. Voxel-Based Morphometry (VBM) was employed to investigate potential differences between groups in grey matter volumes.
Results: VBM located the most significant difference between SCZ and HCs in the left medial frontal gyrus, where SCZ>10 group showed a significant reduction of grey matter volume; the same cluster resulted significantly decreased in DEL group compared to HCs as well. Despite the extensive grey matter abnormalities observed in 22q11.2DS, the DEL group showed the only significant differences compared to the SCZ>10 group in the right lingual gyrus volumes.
Conclusions: Despite the small sample, our study identified a common area of grey matter loss both in idiopathic schizophrenia and 22q11.2DS.
期刊介绍:
Gli interessi della rivista riguardano l’approfondimento delle interazioni tra mente e malattia, la validazione e la discussione dei nuovi strumenti e parametri di classificazione diagnostica, la verifica delle prospettive terapeutiche farmacologiche e non.